المؤلفون: Glaviano, Antonino, Foo, Aaron, Lam, Hiu, Yap, Kenneth, Jacot, William, Jones, Robert, Eng, Huiyan, Nair, Madhumathy, Makvandi, Pooyan, Geoerger, Birgit, Kulke, Matthew, Baird, Richard, Prabhu, Jyothi, Carbone, Daniela, Pecoraro, Camilla, Teh, Daniel, Sethi, Gautam, Cavalieri, Vincenzo, Lin, Kevin, Javidi-Sharifi, Nathalie, Toska, Eneda, Davids, Matthew, Brown, Jennifer, Diana, Patrizia, Stebbing, Justin, Kumar, Alan, Fruman, David

المصدر: Molecular Cancer. 22(1)

مصطلحات موضوعية: AKT inhibitors, ATP-competitive mTOR inhibitors, Allosteric mTOR inhibitors, Bi-steric mTOR inhibitors, Cancer, Dual PI3K/mTOR inhibitors, Isoform-specific PI3K inhibitors, PDK1 inhibitors, PI3K/AKT/mTORC pathway, Pan PI3K inhibitors, Humans, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, Signal Transduction, TOR Serine-Threonine Kinases, Neoplasms

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/3x80g7hpTest

المصدر: Drug Week; 1/5/2024, p418-418, 1p

مصطلحات موضوعية: RENAL cell carcinoma, RENAL cancer, NEUROBLASTOMA, CHILDHOOD cancer, MTOR inhibitors

مصطلحات جغرافية: BALTIMORE (Md.)

الشركة/الكيان: JOHNS Hopkins University

المؤلفون: Gkountakos, Anastasios, Pilotto, Sara, Mafficini, Andrea, Vicentini, Caterina, Simbolo, Michele, Milella, Michele, Tortora, Giampaolo, Scarpa, Aldo, Bria, Emilio, Corbo, Vincenzo

المصدر: Carcinogenesis; Aug2018, Vol. 39 Issue 8, p971-980, 10p

مصطلحات موضوعية: RAPAMYCIN, CARCINOGENESIS, MTOR inhibitors, MTOR protein, CATALYTIC activity, GENETIC overexpression

المؤلفون: Seyed Mohammad Abedi, Samaneh Vaseghi, Nasrin Abbasi Gharibkandi, Alireza Mardanshahi, Sajjad Molavipordanjani

المصدر: Molecular Biology Reports. 48:1-14

مصطلحات موضوعية: Cell Survival, medicine.medical_treatment, Apoptosis, Radiation Tolerance, Phosphatidylinositol 3-Kinases, Cell Line, Tumor, Neoplasms, Autophagy, Genetics, medicine, Humans, Radiosensitivity, Protein Kinase Inhibitors, Molecular Biology, Protein kinase B, PI3K/AKT/mTOR pathway, Cell Proliferation, Phosphoinositide-3 Kinase Inhibitors, Cell growth, Akt/PKB signaling pathway, business.industry, TOR Serine-Threonine Kinases, Cell Cycle, Cancer, MTOR Inhibitors, General Medicine, medicine.disease, Radiation therapy, Cancer research, business, Proto-Oncogene Proteins c-akt, Signal Transduction

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18fdb87979d16875fbb742eee534b74bTest
https://doi.org/10.1007/s11033-021-06607-3Test

المؤلفون: Crook, T¹ (AUTHOR), Vaid, A² (AUTHOR), Limaye, S³ (AUTHOR), Page, R⁴ (AUTHOR), Patil, D⁵ (AUTHOR), Akolkar, D⁵ (AUTHOR), Datta, V⁵ (AUTHOR), Ghaisas, A⁵ (AUTHOR), Patil, R⁵ (AUTHOR), Singh, H⁵ (AUTHOR), Srinivasan, A⁵ (AUTHOR), Apurwa, S⁵ (AUTHOR), Datar, R⁵ (AUTHOR)

المصدر: Annals of Oncology. 2019 Supplement, Vol. 30, pN.PAG-N.PAG. 1p.

مصطلحات موضوعية: *MTOR inhibitors, *CANCER genetics, *PART-time employment, *TRANSCRANIAL direct current stimulation, *CANCER

المؤلفون: Karla B Neves, Jorie Versmissen, Ron H.J. Mathijssen, Joerg Herrmann, Sandra M. Herrmann, Ninian N. Lang, Stephen J.H. Dobbin, Daan C.H. van Dorst, A.H. Jan Danser

المساهمون: Internal Medicine, Medical Oncology, Pharmacy

المصدر: Circulation Research
Circulation Research, 1040-1061. Lippincott Williams & Wilkins
STARTPAGE=1040;ENDPAGE=1061;ISSN=0009-7330;TITLE=Circulation Research

مصطلحات موضوعية: Cancer survivorship, Oncology, Proto-Oncogene Proteins B-raf, Vascular Endothelial Growth Factor A, medicine.medical_specialty, hypertension, Physiology, Cardiovascular health, neoplasms, Antineoplastic Agents, Platinum Compounds, 030204 cardiovascular system & hematology, Poly(ADP-ribose) Polymerase Inhibitors, 03 medical and health sciences, 0302 clinical medicine, Cancer Survivors, SDG 3 - Good Health and Well-being, Risk Factors, Internal medicine, Agammaglobulinaemia Tyrosine Kinase, Medicine, Humans, In patient, Risk factor, Carcinoma, Renal Cell, business.industry, Proto-Oncogene Proteins c-ret, Cancer, angiogenesis inhibitors, MTOR Inhibitors, medicine.disease, Comorbidity, Optimal management, Cardiotoxicity, Kidney Neoplasms, Hypertension Compendium, comorbidity, Increased risk, 030220 oncology & carcinogenesis, prognosis, Cardiology and Cardiovascular Medicine, business, Proteasome Inhibitors

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dcc8b836778a89de3b7917233f2840cTest
https://eprints.gla.ac.uk/234068/1/234068.pdfTest

المؤلفون: Olivier Tredan, Cecile Vicier, Thibault Dayris, Olivia Fromigué, Ibrahim Bouakka, Bojana Stefanovska, Véronique Scott, Anna Rocca, Olivia Le Saux, Fabrice Andre, Suzette Delaloge, Thomas Bachelot, Vasily Ogryzko

المساهمون: Prédicteurs moléculaires et nouvelles cibles en oncologie (PMNCO), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut Gustave Roussy (IGR), Aspects métaboliques et systémiques de l'oncogénèse pour de nouvelles approches thérapeutiques (METSY), Institut Gustave Roussy (IGR)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Département de médecine oncologique [Gustave Roussy], Centre National de la Recherche Scientifique (CNRS), Département d'Oncologie Médicale [Lyon] ( Centre Léon Bérard), Centre Léon Bérard [Lyon], FROMIGUE, OLIVIA

المصدر: Cancer Research
Cancer Research, American Association for Cancer Research, 2020, 80 (11), pp.2190-2203. ⟨10.1158/0008-5472.CAN-19-2366⟩
Cancer Research, 2020, 80 (11), pp.2190-2203. ⟨10.1158/0008-5472.CAN-19-2366⟩

مصطلحات موضوعية: Cancer Research, Spliceosome, mTOR inhibitors, RNA splicing, Gustave Roussy (taxe d'apprentissage), Down-Regulation, Gene Expression, Antineoplastic Agents, Cell Cycle Proteins, [SDV.CAN]Life Sciences [q-bio]/Cancer, Protein Serine-Threonine Kinases, Biology, 03 medical and health sciences, 0302 clinical medicine, Opération Parrains Chercheurs, Downregulation and upregulation, [SDV.CAN] Life Sciences [q-bio]/Cancer, Cell Line, Tumor, Neoplasms, Odyssea, Dassault Foundation, medicine, Humans, Everolimus, Breast, Promoter Regions, Genetic, Psychological repression, PI3K/AKT/mTOR pathway, 030304 developmental biology, mammalian target of rapamycin, Sirolimus, 0303 health sciences, Kinase, TOR Serine-Threonine Kinases, FKBP Financial support: This work was supported by INSERM, RNA-Binding Proteins, Cancer, medicine.disease, 3. Good health, Repressor Proteins, Oncology, TRIB3, 030220 oncology & carcinogenesis, MCF-7 Cells, Cancer research, Rapalogs regulate pre-mRNA splicing TRB3

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf0c777d140ecb278ed542caff1cb62fTest
https://www.hal.inserm.fr/inserm-02768801/file/2190.full.pdfTest

المؤلفون: Glaviano, A, Foo, ASC, Lam, HY, Yap, KCH, Jacot, W, Jones, RH, Eng, H, Nair, MG, Makvandi, P, Geoerger, B, Kulke, MH, Baird, RD, Prabhu, JS, Carbone, D, Pecoraro, C, Teh, DBL, Sethi, G, Cavalieri, V, Lin, KH, Javidi-Sharifi, NR, Toska, E, Davids, MS, Brown, JR, Diana, P, Stebbing, J, Fruman, DA, Kumar, AP

المساهمون: CANCER SCIENCE INSTITUTE OF SINGAPORE, MICROBIOLOGY AND IMMUNOLOGY, PHARMACOLOGY, PHYSIOLOGY

المصدر: Elements

مصطلحات موضوعية: AKT inhibitors, ATP-competitive mTOR inhibitors, Allosteric mTOR inhibitors, Bi-steric mTOR inhibitors, Cancer, Dual PI3K/mTOR inhibitors, Isoform-specific PI3K inhibitors, PDK1 inhibitors, PI3K/AKT/mTORC pathway, Pan PI3K inhibitors, Humans, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, Signal Transduction, TOR Serine-Threonine Kinases, Neoplasms

العلاقة: Glaviano, A, Foo, ASC, Lam, HY, Yap, KCH, Jacot, W, Jones, RH, Eng, H, Nair, MG, Makvandi, P, Geoerger, B, Kulke, MH, Baird, RD, Prabhu, JS, Carbone, D, Pecoraro, C, Teh, DBL, Sethi, G, Cavalieri, V, Lin, KH, Javidi-Sharifi, NR, Toska, E, Davids, MS, Brown, JR, Diana, P, Stebbing, J, Fruman, DA, Kumar, AP (2023-12-01). PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Molecular Cancer 22 (1) : 138-. ScholarBank@NUS Repository. https://doi.org/10.1186/s12943-023-01827-6Test; https://scholarbank.nus.edu.sg/handle/10635/245930Test

الإتاحة: https://doi.org/10.1186/s12943-023-01827-6Test
https://scholarbank.nus.edu.sg/handle/10635/245930Test

المؤلفون: Ji Nie, Xuelei Ma, Jing Yang, Xiawei Wei, Yong Peng, Yuquan Wei

المصدر: Molecular Cancer
Molecular Cancer, Vol 18, Iss 1, Pp 1-28 (2019)

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, Antineoplastic Agents, Review, Biology, lcsh:RC254-282, PI3K signaling, PI3K, Target therapy, 03 medical and health sciences, Phosphatidylinositol 3-Kinases, 0302 clinical medicine, Neoplasms, medicine, Animals, Humans, Molecular Targeted Therapy, Protein kinase B, Protein Kinase Inhibitors, PI3K/AKT/mTOR pathway, Cancer, Phosphoinositide-3 Kinase Inhibitors, Clinical Trials as Topic, TOR Serine-Threonine Kinases, Master regulator, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Discovery and development of mTOR inhibitors, Clinical trial, Gene Expression Regulation, Neoplastic, 030104 developmental biology, Oncology, Tumor progression, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Cancer research, mTOR, Molecular Medicine, Proto-Oncogene Proteins c-akt, Signal Transduction

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::760fbcdfb07da0c9e7201f544add6b61Test
http://europepmc.org/articles/PMC6379961Test

المؤلفون: Jennifer J. Wheler, Apostolia Maria Tsimberidou, Aung Naing, Vivek Subbiah, Siqing Fu, Razelle Kurzrock, Susan Kambrick, Bonnie S. Glisson, Sarina Anne Piha-Paul, Ralph Zinner, Xiaochun Liu, George R. Blumenschein, David S. Hong, Merrill S. Kies

المصدر: Oncotarget
Oncotarget, vol 7, iss 17
Liu, X; Kambrick, S; Fu, S; Naing, A; Subbiah, V; Blumenschein, GR; et al.(2016). Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. ONCOTARGET, 7(17), 23227-23238. doi: 10.18632/oncotarget.7594. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/3xx7q8fsTest

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Maximum Tolerated Dose, Bevacizumab, Oncology and Carcinogenesis, Cetuximab, and over, bevacizumab, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Internal medicine, temsirolimus, Antineoplastic Combined Chemotherapy Protocols, 80 and over, medicine, Humans, PI3K/AKT/mTOR pathway, Aged, Aged, 80 and over, Sirolimus, Hematology, business.industry, Cancer, solid tumors, Middle Aged, Prognosis, medicine.disease, Discovery and development of mTOR inhibitors, Temsirolimus, Surgery, Survival Rate, 030104 developmental biology, 030220 oncology & carcinogenesis, Female, business, Hypophosphatemia, Research Paper, Follow-Up Studies, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a46d89e727927f9fdb71c1ce8e76522Test
https://doi.org/10.18632/oncotarget.7594Test